BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34143886)

  • 21. Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.
    Moon JH; Choi JY; Jeong WJ; Ahn SH; Lee WW; Kim KM; Choi SH; Lim S; Park YJ; Yi KH; Park do J; Jang HC
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):459-65. PubMed ID: 26833982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma.
    Wang C; Zhang R; Wang R; Meng Z; Zhang G; Dong F; He Y; Tan J
    Front Endocrinol (Lausanne); 2021; 12():667544. PubMed ID: 34040584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer.
    Tian T; Jiang L; Zhang X; Huang R; Liu B
    Surgery; 2020 Dec; 168(6):1095-1100. PubMed ID: 32948335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
    Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
    Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
    Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer.
    Wu S; Wang H
    Ann Endocrinol (Paris); 2013 Feb; 74(1):40-4. PubMed ID: 23337017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later.
    Melo M; Costa G; Ribeiro C; Carrilho F; Martins MJ; da Rocha AG; Sobrinho-Simões M; Carvalheiro M; Soares P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4364-72. PubMed ID: 24037891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Value of Stimulated Thyroglobulin Before the First Radioactive Iodine Treatment in Metastasis for Differentiated Thyroid Carcinoma.
    Ren L; Zhang C; Shen Y; Mo A; Hu Y; Sun J; Yuan C; Wen W
    Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.
    Piccardo A; Arecco F; Puntoni M; Foppiani L; Cabria M; Corvisieri S; Arlandini A; Altrinetti V; Bandelloni R; Orlandi F
    Clin Nucl Med; 2013 Jan; 38(1):18-24. PubMed ID: 23242039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
    Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
    J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.
    Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S
    Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin.
    Liu L; Huang F; Liu B; Huang R
    J Pediatr Endocrinol Metab; 2018 Jul; 31(7):751-756. PubMed ID: 29953410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
    Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
    Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.
    Wang R; Zhang Y; Tan J; Zhang G; Zhang R; Zheng W; He Y
    Medicine (Baltimore); 2017 May; 96(19):e6809. PubMed ID: 28489758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.